DOMH vs. IMNN, COSM, ERNA, CHRO, CHEK, TRIB, AKTX, BIMI, COEP, and PETV
Should you be buying Dominari stock or one of its competitors? The main competitors of Dominari include Imunon (IMNN), Cosmos Health (COSM), Eterna Therapeutics (ERNA), Chromocell Therapeutics (CHRO), Check-Cap (CHEK), Trinity Biotech (TRIB), Akari Therapeutics (AKTX), BIMI (BIMI), Coeptis Therapeutics (COEP), and PetVivo (PETV). These companies are all part of the "medical" sector.
Dominari (NASDAQ:DOMH) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, community ranking, earnings, risk and institutional ownership.
Dominari has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, Imunon has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500.
Imunon has a net margin of 0.00% compared to Dominari's net margin of -721.11%. Dominari's return on equity of -38.40% beat Imunon's return on equity.
42.5% of Dominari shares are held by institutional investors. Comparatively, 4.5% of Imunon shares are held by institutional investors. 9.7% of Dominari shares are held by company insiders. Comparatively, 5.0% of Imunon shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Imunon had 9 more articles in the media than Dominari. MarketBeat recorded 9 mentions for Imunon and 0 mentions for Dominari. Imunon's average media sentiment score of 0.12 beat Dominari's score of 0.00 indicating that Imunon is being referred to more favorably in the news media.
Imunon has lower revenue, but higher earnings than Dominari. Imunon is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.
Imunon has a consensus target price of $12.00, suggesting a potential upside of 745.07%. Given Imunon's higher probable upside, analysts plainly believe Imunon is more favorable than Dominari.
Imunon received 9 more outperform votes than Dominari when rated by MarketBeat users.
Summary
Imunon beats Dominari on 10 of the 16 factors compared between the two stocks.
Get Dominari News Delivered to You Automatically
Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dominari Competitors List
Related Companies and Tools
